The outbreak of the COVID-19 virus pandemic in Indonesia continues to be a problem that affects people's daily activities. Moreover, recently the news that the 3rd wave of COVID-19 in Indonesia has become its own shadow in the current pandemic situation.

Along with that, DNR Corporation also provides its best business services to overcome the situation during the current pandemic in Indonesia.

In fact, it is rumored that information from the COVID-19 Handling Task Force (Satgas) that the 3rd wave of COVID-19 in Indonesia will potentially be in the next few months of 2021. In this case, the COVID-19 Task Force stated the need for overall vigilance against the third wave of the COVID-19 virus.

DNR Corporation Has a Strategic Plan to Distribute NRICM101

In line with this, DNR Corporation has joined in the response to the pandemic outbreak that has been rolling since the past few years. The company, which is now under the auspices of PT Zebra Nusantara Tbk (ZBRA), strives to provide the best pharmaceutical product distribution services in order to have a real countermeasure impact.

"DNR will always continue to synergize with all parties and provide qualified pharmaceutical distribution services, especially during the COVID-19 pandemic outbreak and its challenges like today," said Gary Tanoesoedibjo as Director of DNR Corporation.

In line with this, DNR has future strategic plans in distributing one of the COVID-19 drugs in Indonesia called NRICM101. NRICM101 itself is an herbal medicine formula developed by the National Research Institute of Chinese Medicine (NRICM) in 2020 in Taiwan with the main effect of preventing virus replication and suppressing the incidence of cytokine storms.

In Taiwan itself, NRICM101 can currently be known by the brand name Coflu Remedy, the use of which has been used by the public in the current situation of the COVID-19 pandemic outbreak.

NRICM101 Herbal Medicine Can Have an Impact on Handling COVID-19

In its development, NRICM101 herbal medicine can be used as a complementary treatment along with modern medicine. NRICM101 can inhibit the infection process of the virus and suppress its inflammatory effects, making a considerable impact on the country's COVID-19 exposure rate.

From the available data, NRICM101 itself can reduce the death rate in Taiwan due to exposure to COVID-19. Existing data reports that Taiwan has a total of 16,205 cases of COVID-19 with a death rate of only 842 people.

This good effectiveness results from the anti-viral and anti-inflammatory effects of the herbs used so that NRICM101 can inhibit the development of the SARS-COV-2 virus.

Especially for people exposed to COVID-19, the research targets people with mild to severe symptoms of COVID-19. In addition to people with COVID-19, this herbal medicine can also be used by people who are at high risk of exposure to COVID-19 in their daily activities.

This NRICM101 traditional medicine in its research conducted by the NRICM agency itself can be useful in preventing and healing from exposure to the COVID-19 virus in the body.

The safety of this herbal medicine to be used together with modern medicine and safe for patients with comorbidities, makes NRICM101 has been used by people in many countries such as the United States, Australia, several countries in Asia, and even in several countries in Europe to reduce the number of COVID-19 in each of these countries.

DNR Strategizes NRICM101 Distribution in Indonesia

The presence of NRICM101 is certainly expected to have a positive impact and can provide real health actions in handling and preventing COVID-19 in Indonesia.

In this case, DNR, which is supported by a distribution network spread throughout Indonesia, is preparing itself to be able to distribute this herbal medicine to Indonesians in all corners of the country.

"With the network owned by DNR in almost 3,000 health facilities spread throughout Indonesia, DNR is preparing with its distribution network to later be able to distribute NRICM101 which is expected to be beneficial for health and especially in treating COVID-19 evenly in 34 provinces in Indonesia," Gary Tanoesoedibjo said in his information.